P
UTHR icon

&Partners’s United Therapeutics UTHR Stock Holding History

&Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.49M Buy
6,447
+937
+17% +$528K 0.01% 743
2026
Q1 		$3.33M Buy
5,510
+2,072
+60% +$1.03M 0.02% 685
2025
Q4 		$1.68M Buy
3,438
+1,656
+93% +$771K 0.01% 944
2025
Q3 		$747K Sell
1,782
-25
-1% -$8.41K ﹤0.01% 1226
2025
Q2 		$520K Buy
1,807
+32
+2% +$9.56K ﹤0.01% 1337
2025
Q1 		$548K Buy
1,775
+509
+40% +$174K 0.01% 1095
2024
Q4 		$453K Buy
1,266
+641
+103% +$236K 0.01% 1117
2024
Q3 		$224K Buy
+625
New +$211K ﹤0.01% 1254

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

&Partners's UTHR Position: Q2 2026 in Review

&Partners increased its United Therapeutics (UTHR) stake by 17% in Q2 2026, buying an estimated $528K and bringing the position to 6,447 shares worth $3.49M. The position accounts for 0.01% of the portfolio, ranked #743.

&Partners first reported a position in UTHR in Q3 2024 and has held it in 8 quarters since. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • &Partners held 6,447 shares of United Therapeutics worth $3.49M as of Q2 2026.
  • &Partners bought 937 United Therapeutics shares in Q2 2026, an estimated $528K.
  • United Therapeutics made up 0.01% of &Partners's portfolio in Q2 2026, its #743 holding.
  • &Partners first reported a position in United Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.